Uroplakin III

Uroplakin III is present in the urothelial surface membrane of human renal pelvis, ureter, bladder and urethra. Uroplakin III [BC17] demonstrated a higher sensitivity compared with [AU1] on urothelial transitional cell carcinomas, in in-house studies. [BC17] staining was negative in all normal and neoplastic tissues except for bladder; hence it is highly specific to uroepithelial tumors and may be a useful tool in the discrimination of bladder, renal and prostate cancers. Loss of Uroplakin III expression in bladder cancers has been associated with higher grade, muscle-invasive cancer and lymphovascular invasion. Uroplakin III [BC17] may be used in a panel of antibodies including GATA3, p63 and S100P. PATENT PENDING.

Specifications

Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.

1. Matsumoto K, et al. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 2008 Aug; 72(2):444-9.
2. Koga F, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003 Nov 15; 9(15):5437-41.
3. Brown HM, et al. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum Pathol. 2002 May; 33 (5):545-8.
4. Riedel I, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch. 2001 Feb; 438(2):181-91.
5. Moll R, et al. Uroplakin III, a specific membrane protein of urothelial umbrella cells, as a histological markers for metastatic transitional cell carcinomas. Verh Dtsch Ges Pathol. 1993; 77:260-5.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.